Dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology cancer drugs, as of April 2018 BeiGene has over 900 employees, three marketed products in China and 12 pivotal trials ongoing globally or in China for its three late-stage clinical drug candidates.
To accomplish its goals when it originally started in China, BeiGene needed a strong and collaborative team of advisors to guide the company through its formation, private financings, initial public offering and beyond.
BeiGene has been a Goodwin client from the beginning. Goodwin helped form BeiGene, raise private capital, complete its initial public offering in the U.S. at the time when the U.S. markets were extremely challenging, and secure additional financing through follow-on offerings. In 2016, when BeiGene had 215 employees, Goodwin assembled a cross-office, cross-practice group, led by its Life Sciences team, to advise BeiGene on its $158 million initial public offering.
Along the way, Goodwin’s Life Sciences team advised BeiGene in three follow-on transactions raising over $1 billion and assisted the company in a global strategic oncology collaboration with Celgene. Most recently, Goodwin’s Life Sciences team advised BeiGene on its $800 million public offering in January 2018.
The additional funding allows BeiGene to continue advancing and expanding its pipeline of novel oral small molecules and monoclonal antibodies in the fight against cancer and prepare for launch of its internally developed drug candidates in the United States and China. Today, BeiGene continues to enjoy extraordinary growth and has a market cap of approximately $9 billion (as of April 12, 2018).